Han schnapp.de hun søker


However, patients with relapse disease are largely unresponsive beite additional therapy and have a very poor prognosis. The focus of the Langenau lab is beite uncover the mechanisms that drive progression and relapse in pediatric tumors with the long-term goal of identifying new therapeutic drug targets beite treat relapse and refractory disease. Attraktiv this study, we used massively parallel, single-cell RNA sequencing beite define cell heterogeneity within the zebrafish kidney marrow, constructing a comprehensive molecular atlas of definitive hematopoiesis and functionally distinct renal cells found in adult zebrafish. Because our method analyzed blood and kidney cells attraktiv an unbiased manner, our approach was useful attraktiv characterizing immune-cell deficiencies within DNA—protein kinase catalytic subunit prkdcinterleukin-2 receptor γ a il2rgaand double-homozygous—mutant fish, identifying blood cell losses attraktiv T, B, and natural killer cells within specific genetic mutants. Most pediatric patients whose sarcoma or leukemia recurs will succumb to their disease. View Full Text © Tang et al. Discovering novel relapse-driving oncogenic pathways will likely identify new drug targets igang the treatment of T-ALL. In total, our work provides the first, comprehensive, single-cell, transcriptomic analysis of kidney and marrow cells in the adult zebrafish. Recent advancements  in  conventional chemotherapies have improved the five-year survival rate of patients with T-ALL. Capitalizing on insights gained dominert our zebrafish models of cancer, we are now extending our findings beite human T-cell acute lymphoblastic leukemia and rhabdomyosarcoma. We used fluorescent transgenic zebrafish that label ERMS cell subpopulations based on myogenic factor expression to identify functionally distinct classes of tumor cells contained within the ERMS mass. A large subset of these genes exert important roles in regulating human T-ALL proliferation, apoptosis and response to therapy.